<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02517541</url>
  </required_header>
  <id_info>
    <org_study_id>CP259</org_study_id>
    <nct_id>NCT02517541</nct_id>
  </id_info>
  <brief_title>A Clinical Investigation Evaluating and Understanding Parameters Affecting the Performance of Ostomy Products</brief_title>
  <official_title>A Clinical Investigation Evaluating and Understanding Parameters Affecting the Performance of Ostomy Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coloplast A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to obtain an understanding of relevant parameters affecting the
      performance of ostomy products.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      72 subjects will be included. Each subject will attend 3 visits at the clinic/hospital or at
      the subjects home depending on the final site set-up. Each subject will be enrolled for 14
      weeks in total for the entire investigation.

      Coloplast will provide SenSura Mio Convex Soft for all subjects via the investigator. Based
      on the subjects' usual changing pattern, the investigator will provide the subjects with
      enough products for the whole test period.

      The subject will answer questions regarding the tested products by filling out the subject
      part in the eCRF daily. The subject will answer questions using an electronic device and use
      the device to take pictures of the peristomal skin and used products at each product change.
      The Investigator fills out the investigator part of the eCRF at each visit. The subjects must
      complete the general questions at the end of each test period before their second and third
      visit at the Clinic/hospital or at home to avoid influence by the investigator.

      The use of accessories will be noted in the eCRF. Samples of biological material will not be
      taken or used in this investigation. Patient files from own physician will not be used for
      subjects recruited via a Coloplast's database. The investigators may use patient files for
      subjects recruited via hospital sites/ostomy clinics to identifying relevant subjects and/or
      to verify baseline information, concomitant medication or adverse events. To be able to
      fulfil the objectives, the investigation must include both ileostomists and colostomists.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leakage Under the Baseplate (cm^2)</measure>
    <time_frame>14 weeks (2 weeks baseline + 12 weeks intervention)</time_frame>
    <description>The leakage area was measured using photos of used baseplates. A computer program was used to measure the leakage area.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Ileostomy - Stoma</condition>
  <condition>Colostomy</condition>
  <arm_group>
    <arm_group_label>Test period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The arm consists of a two-week baseline period where subjects apply their own product and a 12 weeks test period where the subjects apply the intervention (SenSura Mio Convex Soft)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SenSura Mio Convex Soft</intervention_name>
    <description>SenSura Mio Convex Soft is a CE marked ostomy product manufactured by Coloplast</description>
    <arm_group_label>Test period</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have given written informed consent

          -  Be at least 18 years of age and have full legal capacity

          -  Have an ileostomy or colostomy

          -  Have had their ostomy for at least 3 months

          -  Must use 1 piece open or closed ostomy products during the test period

          -  Currently using a 1 piece. flat product

          -  Must be able to use custom cut product

          -  Have intact peristomal skin

          -  Has experienced leakage (seeping) under the baseplate at least three times during the
             last two weeks

          -  Are evaluated to be suitable for a soft convex product

        Exclusion Criteria:

          -  Currently receiving or have within the past 2 month received radio- and/or
             chemotherapy

          -  Currently or having within the past month received topical steroid treatment in the
             peristomal skin area or systemic steroid (tablet/injection) treatment.

          -  Are pregnant or breastfeeding

          -  Participating in other interventional clinical investigations or have previously
             participated in this investigation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camilla F Vibjerg, M.Sc.pharm</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Clinical Operations</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prism research center</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPS Netherlands</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helse Nordbyen</name>
      <address>
        <city>Larvik</city>
        <zip>3269</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Midlands</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pilgrim Hospital</name>
      <address>
        <city>Boston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <zip>G1537AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kettering General hospital</name>
      <address>
        <city>Kettering</city>
        <zip>NN168UZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincon Country hospital</name>
      <address>
        <city>Lincoln</city>
        <zip>LN25QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2015</study_first_posted>
  <results_first_submitted>August 6, 2018</results_first_submitted>
  <results_first_submitted_qc>August 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2018</results_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Period</title>
          <description>The arm consists of a two-week baseline period where subjects apply their own product and a 12 weeks test period where the subjects apply the intervention (SenSura Mio Convex Soft)
SenSura Mio Convex Soft: SenSura Mio Convex Soft is a CE marked ostomy product manufactured by Coloplast</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline Period (Own Product)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Test Period (SenSura Mio Convex Soft)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>One subjects was not suited for the tes</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects who were included in the safety population of the investigation. One subject did not provide baseline data as the subject violated the protocol and terminated the study. Therefore, no baseline data was recorded.</population>
      <group_list>
        <group group_id="B1">
          <title>Test Period</title>
          <description>The arm consists of a two-week baseline period where subjects apply their own product and a 12 weeks test period where the subjects apply the intervention (SenSura Mio Convex Soft)
SenSura Mio Convex Soft: SenSura Mio Convex Soft is a CE marked ostomy product manufactured by Coloplast</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Leakage Under the Baseplate (cm^2)</title>
        <description>The leakage area was measured using photos of used baseplates. A computer program was used to measure the leakage area.</description>
        <time_frame>14 weeks (2 weeks baseline + 12 weeks intervention)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Own Product</title>
            <description>The mean leakage area measured on the subjects own baseplate</description>
          </group>
          <group group_id="O2">
            <title>SenSura Mio Convex Soft</title>
            <description>The mean leakage area measured on SenSura Mio Convex Soft baseplates</description>
          </group>
        </group_list>
        <measure>
          <title>Leakage Under the Baseplate (cm^2)</title>
          <description>The leakage area was measured using photos of used baseplates. A computer program was used to measure the leakage area.</description>
          <units>cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>baseplates</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>baseplates</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="925"/>
                <count group_id="O2" value="796"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="9.8"/>
                    <measurement group_id="O2" value="6.6" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events were collected in the study period (14 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Own Product</title>
          <description>The mean leakage area measured on the subjects own baseplate</description>
        </group>
        <group group_id="E2">
          <title>SenSura Mio Convex Soft</title>
          <description>The mean leakage area measured on SenSura Mio Convex Soft baseplates</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>During a routine visit at the hospital her potassium values were too low so the medical staff decided to keep her overnight and administer potassium by means of an IV drip</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Peristomal skin dermatitis</sub_title>
                <description>Red, eroded peristomal skin</description>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="74"/>
                <counts group_id="E2" events="59" subjects_affected="25" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Zenia M Størling</name_or_title>
      <organization>Scientific and Regulatory affairs</organization>
      <phone>+45 49111869</phone>
      <email>dkzenst@coloplast.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

